Thalys(SH:603716) Sou Hu Cai Jing·2025-11-01 19:21Core Insights - The stock price of Sely Medical (603716) increased by 2.92% to 25.0 CNY as of October 31, 2025, with a market capitalization of 5.254 billion CNY [1] Shareholder Changes - As of September 30, 2025, the number of shareholders reached 79,300, an increase of 33,600 or 73.49% compared to June 30, 2025 [3][6] - The average number of shares held per shareholder decreased from 4,180 to 2,651 shares, with an average holding value of 65,900 CNY [3] Performance Disclosure - For the first three quarters of 2025, the main revenue was 857 million CNY, a year-on-year decrease of 39.64% [4][6] - The net profit attributable to shareholders was -87.2441 million CNY, down 55.72% year-on-year [4][6] - The net profit excluding non-recurring items was -103 million CNY, a significant decline of 292.71% [4] - In Q3 2025, the single-quarter main revenue was 274 million CNY, a year-on-year decrease of 38.41% [4] - The single-quarter net profit attributable to shareholders was -31.1249 million CNY, an increase of 39.27% year-on-year [4] - The single-quarter net profit excluding non-recurring items was -31.9451 million CNY, down 58.6% year-on-year [4] - The company's debt ratio stood at 49.61%, with investment income of 7.3433 million CNY and financial expenses of 34.9823 million CNY, while the gross profit margin was 21.73% [4] Company Announcements - On October 29, 2025, the fifth board of directors held its 22nd meeting, where both the Q3 report and the asset impairment provision were approved unanimously [5][6]